Mission

Immunowake is committed to the development a universal cancer vaccine by generating safer and more effective bi-specific antibodies. Our strategy focuses on waking up the patient’s immune system to recognize and kill cancer cells. Hence, the name Immunowake.

Immunotherapy involves harnessing the body’s immune system to identify and kill cancer cells in the same way pathogens are identified and targeted. The success of PD-1/PD-L1 blockade in cancer immunotherapy demonstrated that patients are capable of generating anti-tumor T-cells. This proved that the cure for cancer can be found inside your body: through your immune system. Within the next five years, the market for immune checkpoint inhibitors is expected to grow to $30-40 billion. However, only 20-30% of patients have been found to successfully respond to current therapies. There is an increasing need to develop stronger therapeutic candidates to fully tap into this market. Immunowake focuses on developing the next generation of bi-specific antibodies for patients who fail to respond to current therapies.

Our novel proprietary antibody design focuses on reducing toxicity while still maintaining anti-tumor efficacy. Our core technology falls into two categories: (1) bi-specific antibody platforms and (2) high-throughput cell-based assays which allow us to rapid screen for effector functions.